TG Therapeutics (NASDAQ:TGTX) Stock Price Crosses Above 200-Day Moving Average of $6.83

TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.83 and traded as high as $6.86. TG Therapeutics shares last traded at $6.59, with a volume of 1,447,417 shares traded.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several recent analyst reports. StockNews.com raised shares of TG Therapeutics to a “sell” rating in a research note on Friday, June 17th. B. Riley lowered their target price on shares of TG Therapeutics from $23.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 13th. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $21.25.

TG Therapeutics Trading Down 3.2 %

The company has a debt-to-equity ratio of 0.53, a current ratio of 4.68 and a quick ratio of 4.68. The stock has a market cap of $884.72 million, a price-to-earnings ratio of -2.82 and a beta of 2.19. The company’s fifty day moving average price is $6.83 and its 200-day moving average price is $6.83.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds have recently bought and sold shares of the stock. Eagle Asset Management Inc. boosted its position in TG Therapeutics by 5.0% in the 1st quarter. Eagle Asset Management Inc. now owns 475,190 shares of the biopharmaceutical company’s stock worth $4,519,000 after purchasing an additional 22,837 shares in the last quarter. Ensign Peak Advisors Inc purchased a new stake in TG Therapeutics in the 4th quarter worth approximately $599,000. Geode Capital Management LLC lifted its position in shares of TG Therapeutics by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 2,309,837 shares of the biopharmaceutical company’s stock valued at $43,886,000 after buying an additional 7,459 shares in the last quarter. Duality Advisers LP purchased a new position in shares of TG Therapeutics during the 1st quarter valued at approximately $994,000. Finally, Lion Point Capital LP lifted its position in shares of TG Therapeutics by 38.3% during the 4th quarter. Lion Point Capital LP now owns 1,160,307 shares of the biopharmaceutical company’s stock valued at $22,045,000 after buying an additional 321,179 shares in the last quarter. Hedge funds and other institutional investors own 72.64% of the company’s stock.

TG Therapeutics Company Profile

(Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

Recommended Stories

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.